血清外来体的microRNA作为一种新型的生物标志物肝癌

StephenW

Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma


Won Sohn1,4, Jonghwa Kim1,4, So Hee Kang1, Se Ra Yang1, Ju-Yeon Cho1, Hyun Chin Cho2, Sang Goon Shim2 and Yong-Han Paik1,3

    1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    2Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
    3Department of Health Science and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Korea

Correspondence: Dr Y-H Paik, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-gu, Seoul 135-710, Korea. E-mail: [email protected]

4These authors contributed equally to this work.

Received 4 December 2014; Revised 17 June 2015; Accepted 19 June 2015
Top of page
Abstract

Recent studies have shown that circulating microRNAs are a potential biomarker in various types of malignancies. The aim of this study was to investigate the feasibility of using serum exosomal microRNAs as novel serological biomarkers for hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We measured the serum exosomal microRNAs and serum circulating microRNAs in patients with CHB (n=20), liver cirrhosis (LC) (n=20) and HCC (n=20). Serum exosomal microRNA was extracted from 500 μl of serum using an Exosome RNA Isolation kit. The expression levels of microRNAs were quantified by real-time PCR. The expression levels of selected microRNAs were normalized to Caenorhabditis elegans microRNA (Cel-miR-39). The serum levels of exosomal miR-18a, miR-221, miR-222 and miR-224 were significantly higher in patients with HCC than those with CHB or LC (P<0.05). Further, the serum levels of exosomal miR-101, miR-106b, miR-122 and miR-195 were lower in patients with HCC than in patients with CHB (P=0.014, P<0.001, P<0.001 and P<0.001, respectively). There was no significant difference in the levels of miR-21 and miR-93 among the three groups. Additionally, the serum levels of circulating microRNAs showed a smaller difference between HCC and either CHB or LC. This study suggests that serum exosomal microRNAs may be used as novel serological biomarkers for HCC.

StephenW

血清外来体的microRNA作为一种新型的生物标志物肝癌


韩元Sohn1,4，Jonghwa Kim1,4，所以熙Kang1，硒镭阳1，菊妍Cho1，炫钦CHO2，桑笨蛋Shim2和咏涵Paik1,3

    医药，三星医疗中心，韩国成均馆大学医学院，首尔，韩国教研室
    医药，三星昌原医院，成均馆大学医学院，昌原，韩国教研室
    卫生科学与技术，三星电子高级卫生研究院科技，成均馆大学，首尔，韩国3Department

函授：YH博士白先生，医学系，三星医疗中心，韩国成均馆大学医学院，81 Irwon滚装，江南区，首尔135-710，韩国。电子信箱：[email protected]

4These作者同等贡献这项工作。

接受4 2014年12月;修订2015年6月17日;接受19 2015年6月
返回页首
抽象的

最近的研究已经表明，循环微小RNA是在各种类型的恶性肿瘤的一个潜在的生物标志物。这项研究的目的是探讨利用血清外来体的microRNA作为一种新型的血清学标志物用于治疗慢性乙型肝炎（CHB）肝细胞肝癌（HCC）的可行性。我们测量血清外体microRNA和血循环的microRNA在慢性乙肝患者（20例），肝硬化（LC）（N = 20）和HCC（N = 20）。血清外来体小分子RNA是由500微升血清使用外来体RNA提取试剂盒提取。微RNA的表达水平通过实时PCR定量。选择的microRNA的表达水平正常化，以秀丽隐杆线虫的microRNA（CEL-MIR-39）。外来体的miR-18a的血清中，miR-221中，miR-222和miR-224是显著高于HCC患者比那些有慢性乙型肝炎或LC（P <0.05）。此外，外来体的血清水平的miR-101中，miR-106b和的miR-122和miR-195均低于例肝癌患者比CHB患者（P = 0.014，P <0.001，P <0.001和P <0.001，分别）。有在与miR-21和miR-93的水平，三组间无显著差异。此外，循环微小RNA的血清水平表现出HCC，要么CHB或LC相差较小。这项研究表明，血清外来体的microRNA可以作为新型的血清学标志物为肝癌。

StephenW

全文:
http://www.nature.com/emm/journal/v47/n9/full/emm201568a.html

llau_lhf

关注，多谢楼主